Platelet BioGenesis is a biotechnology company in Massachusetts that focuses on developing technology to produce donor-independent human platelets from human induced pluripotent stem cells. Founded 2014 in Chestnut Hill, Massachusetts, United States by Jonathan Thon, Joseph Italiano, and Sven Karlsson, Platelet BioGenesis is a developer of human platelets from stem cells for therapeutic applications. The company's platelets are made using its patented microfluidic bioreactor that permits the production of mature blood cells, under controlled conditions, for transfusion therapy and replaces the need for a human platelet donor, enabling scaled platelet production to meet human clinical need, improved platelet purity to generate bacterial/viral-free and production of immune-compatible human platelets that are safer for human infusion. Platelet BioGenesis has assembled a team comprising experts in cell therapy, gene-editing, and platelet science.
Platelet BioGenesis raises a $26,000,000 series A round from Ziff Capital Partners, eCoast Angel Network, QiMing Venture Partners, Qiming Venture Partners, eCoast Angels, Nest.Bio Ventures and Och-Ziff Capital Management.
Platelet BioGenesis raises a $10,000,000 series A round from Adena Partners I, L.P., Vivo Capital, VI Ventures, eCoast Angels and QiMing Venture Partners.
CEO, Chief Scientific Officer, Co-Founder
President & Chief Executive Officer
Documentaries, videos and podcasts
Boston Harbor Angels
Medical Technology Enterprise Consortium
Ziff Capital Partners